This course has expired. View available courses.
Endocrinology, Medication Management
Case studies in diabetes: Escalating treatment with combination GLP-1RA and insulin
Type 2 diabetes (T2D) is a complex disease that affects many body systems over time. New treatment options and combinations have proven benefits in reducing diabetes-related complications, in addition to their glucose-lowering effects. GLP-1 receptor agonists (GLP-1RAs) comprise another tool in the GP’s toolbox to optimise glycaemic control while accommodating for comorbidities such as elevated […]
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-08-09
Type 2 diabetes (T2D) is a complex disease that affects many body systems over time. New treatment options and combinations have proven benefits in reducing diabetes-related complications, in addition to their glucose-lowering effects.
GLP-1 receptor agonists (GLP-1RAs) comprise another tool in the GP’s toolbox to optimise glycaemic control while accommodating for comorbidities such as elevated cardiovascular risk and body weight.
New PBS reimbursement criteria mean that co-administration of weekly GLP-1RAs and insulin is now possible, presenting a powerful new treatment combination for complex patients.
This program will give you the skills and knowledge to identify patient groups who may benefit from concomitant use of weekly GLP-1RAs and insulin, and to prescribe GLP-1RAs with safety and efficacy in mind.
This program is supported by an independent educational grant provided from Eli Lilly.
Faculty
Dr Anita Sharma, General Practitioner, Queensland.
Dr Ted Wu, Director of the Diabetes Centre, Royal Prince Alfred Hospital.
Prof Richard MacIsaac, Professor and Director of Endocrinology & Diabetes, St. Vincent’s Health.
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Recognise the clinical benefits of GLP1-RAs in treatment of type 2 diabetes (T2D) when combined with insulin therapy
- Identify patient groups likely to benefit from concomitant use of insulin and GLP-1RAs
- Appreciate the potential impact of new Pharmaceutical Benefits Scheme (PBS) reimbursements on the use of weekly GLP-1RAs in clinical practice
- Recognise the role of the GP in optimising T2D outcomes through regular review and treatment escalation as appropriate
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 284625
Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.